Send PM
Followers 766
Posts 52005
Boards Moderated 4
Alias Born 12/12/2004

FREE
RGNX REPORT

Re: None

Monday, 09/13/2021 7:27:19 AM

Monday, September 13, 2021 7:27:19 AM

Post# of 16
AbbVie And REGENXBIO Announce Eye Care Collaboration; AbbVie To Pay REGENXBIO $370M Upfront Payment And Up To $1.38B In milestones
6:31 am ET September 13, 2021 (Benzinga) Print
AbbVie (NYSE:ABBV) and REGENXBIO Inc. (NASDAQ:RGNX) today announced a partnership to develop and commercialize RGX-314, a potential one-time gene therapy for the treatment of wet age-related macular degeneration (wet AMD), diabetic retinopathy (DR) and other chronic retinal diseases. RGX-314 is currently being evaluated in patients with wet AMD in a pivotal trial utilizing subretinal delivery, and in patients with wet AMD and DR in two separate Phase II clinical trials utilizing in-office suprachoroidal delivery.

Under the collaboration, REGENXBIO will be responsible for completion of the ongoing trials of RGX-314. AbbVie and REGENXBIO will collaborate and share costs on additional trials of RGX-314, including the planned second pivotal trial evaluating subretinal delivery for the treatment of wet AMD and future trials. AbbVie will lead the clinical development and commercialization of RGX-314 globally. REGENXBIO shall participate in U.S. commercialization efforts as provided under a mutually agreed upon commercialization plan.

"We are committed to finding solutions for patients living with difficult-to-treat retinal diseases and to helping preserve and protect our patients from visual impairment and devastating vision loss," said Tom Hudson, MD, senior vice president, R&D, chief scientific officer, AbbVie. "In collaboration with REGENXBIO, we aim to make a remarkable impact for the millions of patients suffering from vision loss associated with retinal diseases."

"AbbVie is a strong, complementary partner for REGENXBIO. We expect to leverage AbbVie's global developmental and commercial infrastructure within eye care with our expertise in AAV gene therapy clinical development and deep in-house knowledge of manufacturing and production to continue the development of RGX-314," said Kenneth T. Mills, president and chief executive officer of REGENXBIO.

Under the terms of the agreement, AbbVie will pay REGENXBIO a $370 million upfront payment with the potential for REGENXBIO to receive up to $1.38 billion in additional development, regulatory and commercial milestones. REGENXBIO and AbbVie will share equally in profits from net sales of RGX-314 in the U.S. AbbVie will pay REGENXBIO tiered royalties on net sales of RGX-314 outside the U.S. In addition, REGENXBIO will lead the manufacturing of RGX-314 for clinical development and U.S. commercial supply, and AbbVie will lead manufacturing of RGX-314 for commercial supply outside the U.S.

New York Yankees and Duke Basketball


Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent RGNX News

IQST - iQSTEL Reminds Shareholders To Get Their Votes In Before Annual Meeting Next Week On January 31, 2023 IQST Jan 26, 2023 9:53 AM

Nextech AR's AI-Powered CAD to Poly Toggle3D Launches Major Technology Advancements ARWYF Jan 26, 2023 8:46 AM

UCASU jump-starts its plan of NASDAQ or NYSE up-listing in 2023 UCASU Jan 26, 2023 7:21 AM

Kaya Holdings, Inc. (OTCQB: KAYS) Launches Fifth Dimension Therapeutics™ to seek to Provide Innovative Psychedelic-Based Treatments for Depression and Anxiety Related Conditions and Address the Growing Multi-Billion Dollar Global Psychedelics Market KAYS Jan 25, 2023 10:53 AM

B2 Digital's B2 SPORTS NETWORK (B2SN) Expands Distribution to Europe, Russia, and Asia with StayLIVE Agreement BTDG Jan 25, 2023 10:00 AM

Hebrew University' Yissum and Israeli Biotech Clearmind Medicine's Psychedelic-Derived Obesity Treatment Presented by Professor Joseph Tam, D.M.D., Ph.D. at Isranalytica 2023 CMND Jan 25, 2023 8:48 AM

Sika Health and Electromedical Announce Partnership Enabling HSA/FSA Payments on Electromedical eCommerce Site EMED Jan 25, 2023 7:09 AM

AgriFORCE Announces Binding Letter of Intent to Acquire Berry People LLC, Further Strengthening its Brands Division AGRI Jan 24, 2023 9:00 AM

Green Battery Minerals creates lithium-ion battery using esg-friendly graphene technology and enters into memorandum of understanding with graphene star, a uk graphene producer GEM Jan 23, 2023 1:41 PM

Global Arena Holding Updates Shareholders on Subsidiary Company Global Election Services GAHC Jan 23, 2023 10:02 AM

Kona Gold Beverage, Inc Announces 2023 Revenue Projections KGKG Jan 23, 2023 9:00 AM

ARway The Spatial Computing platform for The Metaverse Announces Multiple Pilot Projects for AR Wayfinding ARWY Jan 20, 2023 9:35 AM

Rodedawg International Industries, Inc. (OTC: RWGI) Provides Shareholder Updates RWGI Jan 20, 2023 8:30 AM

HealthLynked Announces Sale of ACO Health Partners HLYK Jan 20, 2023 8:00 AM

UCASU acquires $3M cannabis property and aims at $1M gross profit for 2023 UCASU Jan 19, 2023 10:29 AM